Please assess the completion status of the following clinical trial:

Trial Title: Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patients, diagnosed of ischemic stroke;~* Onset of stroke is less than or equal to 48 hours;~* There are clear signs of neurological deficit: 4≤NIHSS score≤24, and also, the sum of NIHSS score for the upper limb and the lower limb is greater than or equal to 2;~* Patients signed written inform consent~Exclusion Criteria:~* Cranial CT scan finds intracranial bleeding disorders: hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage;~* Iatrogenic stroke;~* Severe disturbance of consciousness: NIHSS category 1a for consciousness is greater than 1；~* The mRS score prior to this onset is greater than 1;~* Transient ischemic attack (TIA);~* SBP after blood pressure control is still greater than or equal to 220 mmHg, or DBP after blood pressure control is still greater than or equal to 120 mmHg;~* Patients with severe mental disorders and dementia;~* ALT or AST is greater than 2.0×ULN or previously known liver diseases, such as acute hepatitis, chronic active hepatitis, liver cirrhosis;~* Serum Creatinine (SCr) is greater than 1.5×ULN, Creatinine Clearance (CrCl) is less than 50 ml/min or previously known severe renal diseases;~* Therapeutic neuroprotective agents have been applied after onset of stroke, including commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam, butyl benzene peptides, Urinary Kallidinogenase;~* Arterial or venous thrombolytic therapy has been applied after onset of stroke;~* Patients with malignant tumors or receiving concurrent antitumor treatment;~* Patients with severe systemic disease, life expectancy is less than 90 days;~* allergic to edaravone , (+)-Borneol or related excipients;~* Pregnant or lactating women;~* Have major surgery within 4 weeks before enrollment;~* Participated in other clinical studies within 30 days before randomization; or participating in other clinical trials at present;~* The investigators consider the patients are not suitable for this trial.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Compound Edaravone (Type: EXPERIMENTAL): Compound Edaravone Injection 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
- Edaravone (Type: ACTIVE_COMPARATOR): Edaravone Injection 30 mg/dose, one dose every 12 hours, continues for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).